Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPX-701 in AML, MDS, or Uveal Melanoma
NCT02743611Phase 2Terminated
- Sponsor
- Bellicum Pharmaceuticals, Inc.
- Start
- Apr 2017
- Primary completion
- Jul 2019
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of BPX-701 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and Uveal melanoma (UM) (2 arms), sponsored by Bellicum Pharmaceuticals, Inc. Primary endpoints: Dose-limiting Toxicity at 28 days and Treatment-emergent Adverse Events and Serious Adverse Events at 15 months. Started Apr 2017; status: terminated.
02
Drugs
BPX-701
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT02743611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02743611.